Treats mild to moderate dementia of the Alzheimer's type. ANDA 90178, held by Sun Pharm. Galantamine Hydrobromide.
As of Nov 15, 2026, ANDA 90178 (Galantamine Hydrobromide), held by Sun Pharm, was first approved by FDA on Feb 2, 2011, with 7 approved supplements and 0 published complete response letters.
Galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2011 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 8MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 16MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 24MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Jan 18, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 15, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 15, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 19, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 31, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 31, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 2, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters